Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-312 Phase 1 in Healthy Volunteers and Parkinson's Disease
NCT04075318Phase 1Completed
- Sponsor
- Vaxxinity
- Start
- Aug 2019
- Primary completion
- Mar 2023
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ub-312 in Parkinson's disease (PD) (11 arms), sponsored by Vaxxinity. Primary endpoints: Frequency of Adverse Events at 44 weeks, Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood at 44 weeks and 1 more. Started Aug 2019; status: completed.
02
Drugs
ub-312
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04075318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075318.